Register
Medicines reference
Active substance

Hydrolysed fish protein (marine oligopeptides)

Amino acid peptide supplement. Not applicable (not a medicine). Forms: suspension.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Hydrolysed fish protein (marine oligopeptides)
Georgian name
თევზის ჰიდროლიზებული ცილა (ზღვის ოლიგოპეპტიდები)
Authorisation status
Complementary feed / supplement
Not a medicine and not required to be authorised as one - it is sold under feed law.
Registered in Georgia
0 of 1 forms
Products
Controlled in Georgia
Unknown
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Pronefra, Suspension

oral suspension, 60 ml and 180 ml, complementary feed for adult dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive enteric phosphate binding in adult dogs with CKD when dietary phosphate restriction alone is insufficient
7.1/10
Good
vetman assessment

Pronefra

oral suspension, 60 ml and 180 ml, complementary feed for adult dogs and cats
Assessed clinical scopeDog · Adjunctive enteric phosphate binding in adult dogs with CKD when dietary phosphate restriction alone is insufficient · By mouth
Care settingVeterinary-directed outpatient CKD management with serial phosphate and calcium monitoring
vetman score 7.1/10 Good
Evidence confidence: Medium Georgia: Not a medicine · Verified on 20 Oct 2026

A practical adjunctive phosphate binder with a transparent formula; use only when the patient needs binding and titrate against laboratory targets.

Regulatory and scientific credibility6.5/10

The current exact formula and species-specific dose are transparent, and its complementary-feed status is correctly documented; it is not a medicinal product and lacks a regulator-reviewed efficacy dossier.

Clinical efficacy6.5/10

Calcium carbonate is a guideline-recognised enteric phosphate binder, but benefit must be titrated to serum phosphate and independent outcome evidence for this exact multi-ingredient product is limited.

Safety and tolerability7.5/10

Sponsor-reported tolerance is generally good, but calcium-containing binders require calcium monitoring and the product should not be used as an unmonitored routine supplement.

Clinical practicality8.5/10

The oral suspension has clear weight-based dosing, is given twice daily with meals and has favourable acceptance data; shaking and accurate syringe measurement remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when dietary phosphate restriction is insufficient; titrate to serum phosphate and monitor calcium.
  • Independent clinical outcome evidence for the exact four-component product is limited.
Assessment sources
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Adjunctive enteric phosphate binding in adult cats with CKD when dietary phosphate restriction alone is insufficient
7.1/10
Good
vetman assessment

Pronefra

oral suspension, 60 ml and 180 ml, complementary feed for adult dogs and cats
Assessed clinical scopeCat · Adjunctive enteric phosphate binding in adult cats with CKD when dietary phosphate restriction alone is insufficient · By mouth
Care settingVeterinary-directed outpatient CKD management with serial phosphate and calcium monitoring
vetman score 7.1/10 Good
Evidence confidence: Medium Georgia: Not a medicine · Verified on 20 Oct 2026

A practical adjunctive phosphate binder with a transparent formula; use only when the patient needs binding and titrate against laboratory targets.

Regulatory and scientific credibility6.5/10

The current exact formula and species-specific dose are transparent, and its complementary-feed status is correctly documented; it is not a medicinal product and lacks a regulator-reviewed efficacy dossier.

Clinical efficacy6.5/10

Calcium carbonate is a guideline-recognised enteric phosphate binder, but benefit must be titrated to serum phosphate and independent outcome evidence for this exact multi-ingredient product is limited.

Safety and tolerability7.5/10

Sponsor-reported tolerance is generally good, but calcium-containing binders require calcium monitoring and the product should not be used as an unmonitored routine supplement.

Clinical practicality8.5/10

The oral suspension has clear weight-based dosing, is given twice daily with meals and has favourable acceptance data; shaking and accurate syringe measurement remain necessary.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when dietary phosphate restriction is insufficient; titrate to serum phosphate and monitor calcium.
  • Independent clinical outcome evidence for the exact four-component product is limited.
Assessment sources
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Formulation Type
Suspension
Administration route
By mouth
Manufacturer
Virbac · France
Registration
Georgia Not a medicine
Not applicable (not a medicine)
In the register: პრონეფრა
Verified on: 20 Oct 2026
Controlled in Georgia
Unknown

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.